Related Experiment Videos
Melioidosis; a treatment challenge
1Sappasitprasong Hospital, Ubon Ratchatani, Thailand.
Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1996
Summary
Melioidosis treatment is challenging, but ceftazidime is effective for severe cases. Longer treatment durations, like 20 weeks, significantly reduce relapse rates for this difficult infection.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Melioidosis is a severe bacterial infection with high mortality.
- Current empirical treatments for septicemia are often ineffective.
- Treatment requires prolonged parenteral administration and can be costly.
Purpose of the Study:
- To evaluate the effectiveness of different antibiotic regimens for melioidosis.
- To determine optimal treatment duration to minimize relapse rates.
- To assess the role of abscess drainage in melioidosis management.
Main Methods:
- Retrospective analysis of patient treatment outcomes.
- Comparison of various antibiotic therapies including ceftazidime, co-amoxyclav, and imipenem.
- Evaluation of relapse rates based on treatment duration and infection extent.
Main Results:
- Ceftazidime significantly reduces mortality in severe melioidosis.
- Empirical treatment with aminoglycosides and penicillin/ampicillin/cephalosporins is ineffective.
- A 20-week treatment course reduces relapse rates to 9%, compared to 28% with 8 weeks.
- Ceftazidime is the drug of choice, with co-amoxyclav and imipenem as alternatives.
Conclusions:
- Ceftazidime is the preferred treatment for severe melioidosis.
- Extended treatment duration (20 weeks) is crucial for reducing relapse.
- Prompt drainage of large abscesses is recommended.
- Life-long follow-up is necessary for survivors of the acute phase.